Как сохранить приверженность к приему антикоагулянта у пациента с фибрилляцией предсердий?
https://doi.org/10.18087/cardio.2019.11.n724
Аннотация
Менее обременительное, по сравнению с варфарином, лечение прямыми пероральными антикоагулянтами (ППОАК) способно привести к лучшей приверженности к терапии больных с фибрилляцией предсердий (ФП). Однако у определенного числа пациентов с ФП, которым рекомендовались ППОАК, рецидивирует кардиоэмболический инсульт, что в значительной степени связано с невыполнением больными врачебных рекомендаций. Назначение ППОАК в качестве препаратов первой линии не гарантирует высокую приверженность больных с неклапанной ФП. Для пациентов с ФП пожилого и старческого возраста с многочисленными сопутствующими заболеваниями предложение более простой схемы фармакотерапии особенно актуально. В ряде крупных современных исследований, выполненных в клинической практике, установлена высокая приверженность к терапии ривароксабаном, которая может быть следствием приема данного ППОАК 1 раз в сутки, его безопасности и эффективности.
Об авторе
С. Г. Канорский
ФГБОУ ВО «Кубанский государственный медицинский университет» Минздрава России
Россия
Краснодар
Россия
Краснодар
Список литературы
1. January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC et al. 2019 AHA/ACC/HRS Focused update of the 2014 AHA/ACC/HRS Guideline for the management of patients with atrial fibrillation. Journal of the American College of Cardiology. 2019;74 (1):104–32. DOI: 10.1016/j.jacc.2019.01.011
2. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal. 2016;37 (38):2893–962. DOI: 10.1093/eurheartj/ehw210
3. Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP et al. Heart Disease and Stroke Statistics – 2019 Update: A Report From the American Heart Association. Circulation. 2019;139 (10):e56–528. DOI: 10.1161/CIR.0000000000000659
4. Bunch TJ, Gersh BJ. Rhythm Control Strategies and the Role of Antiarrhythmic Drugs in the Management of Atrial Fibrillation: Focus on Clinical Outcomes. Journal of General Internal Medicine. 2011;26 (5):531–7. DOI: 10.1007/s1160601015748
5. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A et al. Dabigatran versus warfarin in patients with atrial fibrillation. New England Journal of Medicine. 2009;361 (12):1139–51. DOI: 10.1056/NEJMoa0905561
6. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New England Journal of Medicine. 2011;365 (10):883–91. DOI: 10.1056/NEJMoa1009638
7. Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M et al. Apixaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine. 2011;365 (11):981–92. DOI: 10.1056/NEJMoa1107039
8. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL et al. Edoxaban versus warfarin in patients with atrial fibrillation. The New England Journal of Medicine. 2013;369 (22):2093–104. DOI: 10.1056/NEJMoa1310907
9. Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L et al. The 2018 European Heart Rhythm Association Practical Guide on the use of nonvitamin K antagonist oral anticoagulants in patients with atrial fibrillation. European Heart Journal. 2018;39 (16):1330–93. DOI: 10.1093/eurheartj/ehy136
10. Shinoda N, Mori M, Tamura S, Korosue K, Kose S, Kohmura E. Risk of Recurrent Ischemic Stroke with Unintended LowDose Oral Anticoagulant Therapy and Optimal Timing of Review. Journal of Stroke and Cerebrovascular Diseases. 2018;27 (6):1546–51. DOI: 10.1016/j.jstrokecerebrovasdis.2018.01.002
11. Rodriguez RA, Carrier M, Wells PS. Nonadherence to new oral anticoagulants: a reason for concern during longterm anticoagulation? Journal of Thrombosis and Haemostasis. 2013;11 (2):390–4. DOI: 10.1111/jth.12086
12. McHorney CA, Crivera C, Laliberté F, Germain G, Wynant W, Lefebvre P. Adherence to rivaroxaban versus apixaban among patients with nonvalvular atrial fibrillation: Analysis of overall population and subgroups of prior oral anticoagulant users. PLOS ONE. 2018;13 (4):e0194099. DOI: 10.1371/journal.pone.0194099
13. Alberts MJ, Peacock WF, Fields LE, Bunz TJ, Nguyen E, Milentijevic D et al. Association between once and twicedaily direct oral anticoagulant adherence in nonvalvular atrial fibrillation patients and rates of ischemic stroke. International Journal of Cardiology. 2016;215:11–3. DOI: 10.1016/j.ijcard.2016.03.212
14. Madhavan M, Yao X, Sangaralingham LR, Asirvatham SJ, Friedman PA, McLeod CJ et al. Ischemic Stroke or Systemic Embolism after Transseptal Ablation of Arrhythmias in Patients with Cardiac Implantable Electronic Devices. Journal of the American Heart Association. 2016;5 (4):e003163. DOI: 10.1161/JAHA.115.003163
15. Borne RT, O’Donnell C, Turakhia MP, Varosy PD, Jackevicius CA, Marzec LN et al. Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: findings from the veterans health administration. BMC Cardiovascular Disorders. 2017;17 (1):236. DOI: 10.1186/s1287201706716
16. Deshpande CG, Kogut S, Laforge R, Willey C. Impact of medication adherence on risk of ischemic stroke, major bleeding and deep vein thrombosis in atrial fibrillation patients using novel oral anticoagulants. Current Medical Research and Opinion. 2018;34 (7):1285–92. DOI: 10.1080/03007995.2018.1428543
17. Gellad WF, Thorpe CT, Steiner JF, Voils CI. The myths of medication adherence. Pharmacoepidemiology and Drug Safety. 2017;26 (12):1437–41. DOI: 10.1002/pds.4334
18. Spivey CA, Liu X, Qiao Y, Mardekian J, Parker RB, Phatak H et al. Stroke associated with discontinuation of warfarin therapy for atrial fibrillation. Current Medical Research and Opinion. 2015;31 (11):2021–9. DOI: 10.1185/03007995.2015.1082995
19. HurtadoNavarro I, GarcíaSempere A, RodríguezBernal C, SantaAnaTellez Y, Peiró S, SanfélixGimeno G. Estimating Adherence Based on Prescription or Dispensation Information: Impact on Thresholds and Outcomes. A RealWorld Study With Atrial Fibrillation Patients Treated With Oral Anticoagulants in Spain. Frontiers in Pharmacology. 2018;9:1353. DOI: 10.3389/fphar.2018.01353
20. Maura G, Pariente A, Alla F, Billionnet C. Adherence with direct oral anticoagulants in nonvalvular atrial fibrillation new users and associated factors: a French nationwide cohort study. Pharmacoepidemiology and Drug Safety. 2017;26 (11):1367–77. DOI: 10.1002/pds.4268
21. Tsai K, Erickson SC, Yang J, Harada AS, Solow BK, Lew HC. Adherence, persistence, and switching patterns of dabigatran etexilate. The American Journal of Managed Care. 2013;19 (9):e325–332. PMID: 24449962
22. Shore S, Carey EP, Turakhia MP, Jackevicius CA, Cunningham F, Pilote L et al. Adherence to dabigatran therapy and longitudinal patient outcomes: Insights from the Veterans Health Administration. American Heart Journal. 2014;167 (6):810–7. DOI: 10.1016/j.ahj.2014.03.023
23. BeyerWestendorf J, Ehlken B, Evers T. Realworld persistence and adherence to oral anticoagulation for stroke risk reduction in patients with atrial fibrillation. Europace. 2016;18 (8):1150–7. DOI: 10.1093/europace/euv421
24. Shore S, Ho PM, LambertKerzner A, Glorioso TJ, Carey EP, Cunningham F et al. SiteLevel Variation in and Practices Associated with Dabigatran Adherence. JAMA. 2015;313 (14):1443–50. DOI: 10.1001/jama.2015.2761
25. Thorne K, Jayathissa S, Dee S, Briggs N, Taylor J, Reid S et al. Adherence and outcomes of patients prescribed dabigatran (Pradaxa) in routine clinical practice: Adherence and outcomes of patients. Internal Medicine Journal. 2014;44 (3):261–5. DOI: 10.1111/imj.12370
26. Yamada K, Nabeshima T. Pharmacistmanaged clinics for patient education and counseling in Japan: current status and future perspectives. Journal of Pharmaceutical Health Care and Sciences. 2015;1 (1):2. DOI: 10.1186/s4078001400014
27. Vrijens B, De Geest S, Hughes DA, Przemyslaw K, Demonceau J, Ruppar T et al. A new taxonomy for describing and defining adherence to medications: New taxonomy for adherence to medications. British Journal of Clinical Pharmacology. 2012;73 (5):691–705. DOI: 10.1111/j.1365–2125.2012.04167.x
28. Finkelman BS, French B, Bershaw L, Kimmel SE. Factors affecting time to maintenance dose in patients initiating warfarin. Pharmacoepidemiology and Drug Safety. 2015;24 (3):228–36. DOI: 10.1002/pds.3735
29. Ho PM, Magid DJ, Shetterly SM, Olson KL, Maddox TM, Peterson PN et al. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. American Heart Journal. 2008;155 (4):772–9. DOI: 10.1016/j.ahj.2007.12.011
30. Mochari H, Ferris A, Adigopula S, Henry G, Mosca L. Cardiovascular disease knowledge, medication adherence, and barriers to preventive action in a minority population. Preventive Cardiology. 2007;10 (4):190–5. PMID: 17917515
31. Song X, Sander SD, Varker H, Amin A. Patterns and Predictors of Use of Warfarin and Other Common LongTerm Medications in Patients with Atrial Fibrillation: American Journal Cardiovascular Drugs. 2012;12 (4):245–53. DOI: 10.2165/1163254000000000000000
32. Osterberg L, Blaschke T. Adherence to medication. The New England Journal of Medicine. 2005;353 (5):487–97. DOI: 10.1056/NEJMra050100
33. Johnson ME, Lefèvre C, Collings SL, Evans D, Kloss S, Ridha E et al. Early realworld evidence of persistence on oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a cohort study in UK primary care. BMJ Open. 2016;6 (9):e011471. DOI: 10.1136/bmjopen2016–011471
34. Collings SL, Lefèvre C, Johnson ME, Evans D, Hack G, Stynes G et al. Oral anticoagulant persistence in patients with nonvalvular atrial fibrillation: A cohort study using primary care data in Germany. PLOS ONE. 2017;12 (10):e0185642. DOI: 10.1371/journal.pone.0185642
35. Sørensen R, Jamie Nielsen B, Langtved Pallisgaard J, JiYoung Lee C, TorpPedersen C. Adherence with oral anticoagulation in nonvalvular atrial fibrillation: a comparison of vitamin K antagonists and nonvitamin K antagonists. European Heart Journal – Cardiovascular Pharmacotherapy. 2017;3 (3):151–6. DOI: 10.1093/ehjcvp/pvw048
36. Lip GYH, Pan X, Kamble S, Kawabata H, Mardekian J, Masseria C et al. Discontinuation risk comparison among ‘realworld’ newly anticoagulated atrial fibrillation patients: Apixaban, warfarin, dabigatran, or rivaroxaban. PLOS ONE. 2018;13 (4):e0195950. DOI: 10.1371/journal.pone.0195950
37. Raparelli V, Proietti M, Cangemi R, Lip GYH, Lane DA, Basili S. Adherence to oral anticoagulant therapy in patients with atrial fibrillation: Focus on nonvitamin K antagonist oral anticoagu lants. Thrombosis and Haemostasis. 2017;117 (02):209–18. DOI: 10.1160/TH16100757
38. Miyasaka Y. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114 (2):119–25. DOI: 10.1161/CIRCULATIONAHA.105.595140
39. Andrade JG, Krahn AD, Skanes AC, Purdham D, Ciaccia A, Connors S. Values and Preferences of Physicians and Patients with Nonvalvular Atrial Fibrillation Who Receive Oral Anticoagulation Therapy for Stroke Prevention. Canadian Journal of Cardiology. 2016;32 (6):747–53. DOI: 10.1016/j.cjca.2015.09.023
40. Rosanio S, Keylani AM, D’Agostino DC, DeLaughter CM, Vitarelli A. Pharmacology, benefits, unaddressed questions, and pragmatic issues of the newer oral anticoagulants for stroke prophylaxis in nonvalvular atrial fibrillation and proposal of a management algorithm. International Journal of Cardiology. 2014;174 (3):471–83. DOI: 10.1016/j.ijcard.2014.04.179
41. Rivard L, Khairy P. Mechanisms, Clinical Significance, and Prevention of Cognitive Impairment in Patients With Atrial Fibrillation. Canadian Journal of Cardiology. 2017;33 (12):1556–64. DOI: 10.1016/j.cjca.2017.09.024
42. Diener HC, Hart RG, Koudstaal PJ, Lane DA, Lip GYH. Atrial Fibrillation and Cognitive Function. Journal of the American College of Cardiology. 2019;73 (5):612–9. DOI: 10.1016/j.jacc.2018.10.077
43. Rydén L, Zettergren A, Seidu NM, Guo X, Kern S, Blennow K et al. Atrial fibrillation increases the risk of dementia amongst older adults even in the absence of stroke. Journal of Internal Medicine. 2019;286 (1):101–10. DOI: 10.1111/joim.12902
44. Conen D, Rodondi N, Müller A, Beer JH, Ammann P, Moschovitis G et al. Relationships of Overt and Silent Brain Lesions With Cognitive Function in Patients With Atrial Fibrillation. Journal of the American College of Cardiology. 2019;73 (9):989–99. DOI: 10.1016/j.jacc.2018.12.039
45. Desai NR, Krumme AA, Schneeweiss S, Shrank WH, Brill G, Pezalla EJ et al. Patterns of Initiation of Oral Anticoagulants in Patients with Atrial Fibrillation— Quality and Cost Implications. The American Journal of Medicine. 2014;127 (11):1075–1082.e1. DOI: 10.1016/j.amjmed.2014.05.013
46. Forslund T, Wettermark B, Hjemdahl P. Comparison of treatment persistence with different oral anticoagulants in patients with atrial fibrillation. European Journal of Clinical Pharmacology. 2016;72 (3):329–38. DOI: 10.1007/s002280151983z
47. Yao X, Abraham NS, Alexander GC, Crown W, Montori VM, Sangaralingham LR et al. Effect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation. Journal of the American Heart Association. 2016;5 (2):e003074. DOI: 10.1161/JAHA.115.003074
48. Kim H, Lee YS, Kim TH, Cha MJ, Lee JM, Park J et al. A prospective survey of the persistence of warfarin or NOAC in nonvalvular atrial fibrillation: a COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation (CODEAF). The Korean Journal of Internal Medicine. 2019; [Epub ahead of print]. DOI: 10.3904/kjim.2017.415
49. Vrijens B, Heidbuchel H. Nonvitamin K antagonist oral anticoagulants: considerations on once vs. twicedaily regimens and their potential impact on medication adherence. Europace. 2015;17 (4):514–23. DOI: 10.1093/europace/euu311
50. Kreutz R, Persson PB, Kubitza D, Thelen K, Heitmeier S, Schwers S et al. Dissociation between the pharmacokinetics and pharmacodynamics of oncedaily rivaroxaban and twicedaily apixaban: a randomized crossover study. Journal of Thrombosis and Haemostasis. 2017;15 (10):2017–28. DOI: 10.1111/jth.13801
51. Brown JD, Shewale AR, Talbert JC. Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention for Newly Diagnosed and TreatmentNaive Atrial Fibrillation Patients: An Update Using 2013–2014 Data. Journal of Managed Care & Specialty Pharmacy. 2017;23 (9):958–67. DOI: 10.18553/jmcp.2017.23.9.958
52. Crivera C, Nelson WW, Bookhart B, Martin S, Germain G, Laliberté F et al. Pharmacy quality alliance measure: adherence to nonwarfarin oral anticoagulant medications. Current Medical Research and Opinion. 2015;31 (10):1889–95. DOI: 10.1185/03007995.2015.1077213
53. McHorney CA, Ashton V, Laliberté F, Germain G, Wynant W, Crivera C et al. Adherence to Rivaroxaban Compared with Other Oral Anticoagulant Agents Among Patients with Nonvalvular Atrial Fibrillation. Journal of Managed Care & Specialty Pharmacy. 2017;23 (9):980–8. DOI: 10.18553/jmcp.2017.23.9.980
54. Emren SV, Zoghi M, Berılgen R, Özdemir İH, Çelik O, Çetin N et al. Safety of once or twicedaily dosing of nonvitamin K antagonist oral anticoagulants (NOACs) in patients with nonvalvular atrial fibrillation: A NOACTR study. Bosnian Journal of Basic Medical Sciences. 2018;18 (2):185–90. DOI: 10.17305/bjbms.2017.2279
55. Deshpande CG, Kogut S, Willey C. RealWorld Health Care Costs Based on Medication Adherence and Risk of Stroke and Bleeding in Patients Treated with Novel Anticoagulant Therapy. Journal of Managed Care & Specialty Pharmacy. 2018;24 (5):430–9. DOI: 10.18553/jmcp.2018.24.5.430
56. Brown JD, Shewale AR, Talbert JC. Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention in Incident, TreatmentNaïve Nonvalvular Atrial Fibrillation. Journal of Managed Care & Specialty Pharmacy. 2016;22 (11):1319–29. DOI: 10.18553/jmcp.2016.22.11.1319
57. McHorney CA, Peterson ED, Ashton V, Laliberté F, Crivera C, Germain G et al. Modeling the impact of realworld adherence to oncedaily (QD) versus twicedaily (BID) nonvitamin K antagonist oral anticoagulants on stroke and major bleeding events among nonvalvular atrial fibrillation patients. Current Medical Research and Opinion. 2019;35 (4):653–60. DOI: 10.1080/03007995.2018.1530205
58. Weeda ER, Coleman CI, McHorney CA, Crivera C, Schein JR, Sobieraj DM. Impact of once or twicedaily dosing frequency on adherence to chronic cardiovascular disease medications: A metaregression analysis. International Journal of Cardiology. 2016;216:104–9. DOI: 10.1016/j.ijcard.2016.04.082
59. Martinez BK, Baker WL, Sood NA, Bunz TJ, Meinecke AK, Eriksson D et al. Influence of Polypharmacy on the Effectiveness and Safety of Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2019;39 (2):196–203. DOI: 10.1002/phar.2213
60. Coleman CI, Peacock WF, Bunz TJ, Alberts MJ. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack. Stroke. 2017;48 (8):2142–9. DOI: 10.1161/STROKEAHA.117.017474
61. Staerk L, Gerds TA, Lip GYH, Ozenne B, Bonde AN, Lamberts M et al. Standard and reduced doses of dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation: a nationwide cohort study. Journal of Internal Medicine. 2018;283 (1):45–55. DOI: 10.1111/joim.12683
62. Jacobs MS, Schouten JF, de Boer PT, Hoffmann M, Levin LÅ, Postma MJ. Secondary adherence to nonvitaminK antagonist oral anticoagulants in patients with atrial fibrillation in Sweden and the Netherlands. Current Medical Research and Opinion. 2018;34 (10):1839–47. DOI: 10.1080/03007995.2018.1459528
63. Rossi AP, Facchinetti R, Ferrari E, Nori N, Sant S, Masciocchi E et al. Predictors of selfreported adherence to direct oral anticoagulation in a population of elderly men and women with nonvalvular atrial fibrillation. Journal of Thrombosis and Thrombolysis. 2018;46 (2):139–44. DOI: 10.1007/s1123901816791
64. Hecker J, Marten S, Keller L, Helmert S, Michalski F, Werth S et al. Effectiveness and safety of rivaroxaban therapy in dailycare patients with atrial fibrillation: Results from the Dresden NOAC Registry. Thrombosis and Haemostasis. 2016;115 (05):939–49. DOI: 10.1160/TH15100840
65. Kirchhof P, Radaideh G, Kim YH, Lanas F, Haas S, Amarenco P et al. Global Prospective Safety Analysis of Rivaroxaban. Journal of the American College of Cardiology. 2018;72 (2):141–53. DOI: 10.1016/j.jacc.2018.04.058
Рецензия
При поддержке: АО «БАЙЕР»
Для цитирования:
Канорский С.Г. Как сохранить приверженность к приему антикоагулянта у пациента с фибрилляцией предсердий? Кардиология. 2019;59(11):76-83. https://doi.org/10.18087/cardio.2019.11.n724
For citation:
Kanorskii S.G. How to maintain an adherence to oral anticoagulant in a patient with atrial fibrillation? Kardiologiia. 2019;59(11):76-83. (In Russ.) https://doi.org/10.18087/cardio.2019.11.n724
Просмотров: 794
Послать статью по эл. почте 
Оставить комментарий 